IL273484B2 - A33 antibody compositions and methods of using the same in radioimmunotherapy - Google Patents

A33 antibody compositions and methods of using the same in radioimmunotherapy

Info

Publication number
IL273484B2
IL273484B2 IL273484A IL27348420A IL273484B2 IL 273484 B2 IL273484 B2 IL 273484B2 IL 273484 A IL273484 A IL 273484A IL 27348420 A IL27348420 A IL 27348420A IL 273484 B2 IL273484 B2 IL 273484B2
Authority
IL
Israel
Prior art keywords
container
acceleration
sample
during
cells
Prior art date
Application number
IL273484A
Other languages
English (en)
Hebrew (he)
Other versions
IL273484B1 (en
IL273484A (en
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of IL273484A publication Critical patent/IL273484A/en
Publication of IL273484B1 publication Critical patent/IL273484B1/en
Publication of IL273484B2 publication Critical patent/IL273484B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicinal Preparation (AREA)
IL273484A 2017-09-23 2018-09-21 A33 antibody compositions and methods of using the same in radioimmunotherapy IL273484B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562374P 2017-09-23 2017-09-23
US201762562373P 2017-09-23 2017-09-23
PCT/US2018/052253 WO2019060750A2 (en) 2017-09-23 2018-09-21 A33 ANTIBODY COMPOSITIONS AND METHODS OF USE IN RADIOIMMUNOTHERAPY

Publications (3)

Publication Number Publication Date
IL273484A IL273484A (en) 2020-05-31
IL273484B1 IL273484B1 (en) 2025-08-01
IL273484B2 true IL273484B2 (en) 2025-12-01

Family

ID=65810903

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273484A IL273484B2 (en) 2017-09-23 2018-09-21 A33 antibody compositions and methods of using the same in radioimmunotherapy

Country Status (9)

Country Link
US (2) US11555072B2 (enExample)
EP (1) EP3684369A4 (enExample)
JP (3) JP7303802B2 (enExample)
KR (1) KR102783937B1 (enExample)
CN (1) CN111372590A (enExample)
AU (2) AU2018338322B2 (enExample)
CA (1) CA3076611A1 (enExample)
IL (1) IL273484B2 (enExample)
WO (1) WO2019060750A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
US11122038B1 (en) * 2017-05-18 2021-09-14 United Services Automobile Association (Usaa) Methods and systems for authentication of new users
CN113573782B (zh) 2018-12-21 2025-12-16 Ose免疫疗法公司 针对人pd-1的双功能分子
US20220056135A1 (en) 2018-12-21 2022-02-24 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
AU2019406452B2 (en) 2018-12-21 2021-09-16 Ose Immunotherapeutics Humanized anti-human-PD-1 antibody
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CA3136251A1 (en) 2019-04-08 2020-10-15 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
US20230365636A1 (en) 2020-11-16 2023-11-16 Technische Universität München Bioorthogonal reporter gene system
AU2021381768A1 (en) * 2020-11-18 2023-06-22 Memorial Sloan Kettering Cancer Center Anti-gpa33 multi-specific antibodies and uses thereof
CN116744981A (zh) * 2021-01-13 2023-09-12 豪夫迈·罗氏有限公司 组合疗法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO2016130539A2 (en) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307026B1 (en) 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
WO1994013805A1 (en) * 1992-12-10 1994-06-23 Celltech Limited Humanised antibodies directed against a33 antigen
WO1999055369A1 (en) * 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
CA2579391C (en) * 2004-09-06 2010-10-26 Kirin Beer Kabushiki Kaisha Anti-a33 antibody
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
CA2959436A1 (en) 2014-09-30 2016-04-07 The Medical College Of Wisconsin, Inc. Universal platform for targeting therapies to treat neurological diseases
SG11201708257UA (en) 2015-04-06 2017-11-29 Subdomain Llc De novo binding domain containing polypeptides and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO2016130539A2 (en) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KING D J ET AL,, PREPARATION AND PRECLINICAL EVALUATION OF HUMANISED A33 IMMUNOCONJUGATES FOR RADIOIMMUNOTHERAPY, 1 December 1995 (1995-12-01) *

Also Published As

Publication number Publication date
JP2023138957A (ja) 2023-10-03
JP7303802B2 (ja) 2023-07-05
CA3076611A1 (en) 2019-03-28
JP2020534017A (ja) 2020-11-26
AU2018338322B2 (en) 2025-07-17
AU2018338322A1 (en) 2020-04-09
IL273484B1 (en) 2025-08-01
EP3684369A2 (en) 2020-07-29
EP3684369A4 (en) 2021-06-23
US11555072B2 (en) 2023-01-17
WO2019060750A2 (en) 2019-03-28
KR20200057759A (ko) 2020-05-26
JP2025061650A (ja) 2025-04-11
IL273484A (en) 2020-05-31
US20240327511A1 (en) 2024-10-03
WO2019060750A3 (en) 2019-05-16
KR102783937B1 (ko) 2025-03-24
US20200291112A1 (en) 2020-09-17
CN111372590A (zh) 2020-07-03
AU2025204844A1 (en) 2025-07-17

Similar Documents

Publication Publication Date Title
US12005450B2 (en) Method and apparatus for the reduction of the volume of a sample
CN105722576B (zh) 用于获取血浆的过滤介质以及相关的过滤装置和方法
US10054524B2 (en) Apparatus, system and method for collecting a target material
JP2025138764A (ja) 生体試料の染色システムおよび方法
JP2013545114A (ja) 試料の混合及び分析を容易にするために抗吸着剤を使用する装置及び方法
US20160041077A1 (en) Apparatus, system, and method for collecting a target material
EP1957988B1 (en) Systems and methods for measuring glycated hemoglobin
EP2720798B1 (en) Processing of biological sample components
CA2482560C (en) Centrifugal cytology system, chamber block and method for the preparation of treated monolayers of sample material
US20210170410A1 (en) Devices, systems, and methods for specimen preparation using capillary and centrifugal forces
WO2018140999A1 (en) Method and system for processing a biological sample
EA042126B1 (ru) Способ и устройство для уменьшения объема пробы
HK40046451A (en) Method and apparatus for the reduction of the volume of a sample
HK40046451B (en) Method and apparatus for the reduction of the volume of a sample
KR102637616B1 (ko) 마이크로 유체 장치, 마이크로 유체 시스템 및 입자 분리 방법
EA047610B1 (ru) Способ и устройство для сокращения объема пробы
Zhao et al. Ensemble‐decision Aliquot Ranking (eDAR) for CTC Isolation and Analysis
HK40087736A (en) System, kit, method and process for handling a sample
HK40087736B (en) System, kit, method and process for handling a sample
IL301032A (en) System, kit, method and process for sample handling
HK1176329A (en) Sample processing cartridge and method of processing and/or analysing a sample under centrifugal force